Writing for Morning Consult, Dr. Lucy Langer, a clinical oncologist with Compass Oncology in Portland, Oregon, applauds the administration’s goal of lowering drug prices, but warns of the dangers associated with proposals like the International Pricing Index (IPI) that will – in the words of Dr…

A piece by Peter J. Pitts, a former FDA Associate Commissioner and President of the Center for Medicine in the Public Interest, describes the role of pharmacy benefit managers (PBMs) and tactics they use to shift a growing portion of prescription drug costs to patients and consumers. “In the…

While many were watching the drug pricing debate unfold on Capitol Hill, the Kentucky Cabinet for Health and Family Services published a report exposing drug cost middlemen, better known as pharmacy benefit managers (PBMs), for their role in marking up prices for common drugs and pocketing the…

For years, BIO has been urging both state and federal policymakers to adopt responsible solutions that would make prescription drugs more affordable for America’s patients. At times, our advocacy work includes the need to raise concerns with some of the policy proposals being discussed. That’s the…

Despite considerable pressure directed squarely at biotech innovators from politicians of every stripe, biotech executives remained focused on finding the medicines of tomorrow at the BIO CEO & Investor Conference. New York, host of the event for the past 21 years, continues to be a premier…

In his State of the Union address, President Trump called on Congress to “do more” to lower drug costs in the United States. Already, the U.S. Department of Health and Human Services (HHS) has proposed piloting an International Pricing Index payment model, tying costs for drugs under Medicare Part…

BIO is out with a new report illustrating the negative impact of Sarbanes-Oxley 404(b) on biopharmaceutical emerging growth companies (Bio-EGCs), demonstrating how this regulatory requirement harms innovation and capital formation without any corresponding investor benefit. In the report, Science…

In his State of the Union address, President Trump described the need to rein in health care costs as a “major priority for me.” And for the president, this includes the need to lower the cost of prescription drugs for American patients – an urgent priority also shared by those within the…

Drug prices will be in the spotlight this week as committees in both the House and Senate are set to hold hearings on the cost of prescription drugs. Since this is the first time the new Congress will take a close look at this important issue, here are four facts we encourage policymakers to keep…

At its best, government enables citizens to flourish socially and economically. Above and beyond the basic services we all expect, responsible governments empower citizens to provide for themselves in a rapidly evolving world. Through Senator Birch Bayh’s long career of public service, he led a…